<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bevacizumab is a humanized monoclonal antibody approved by the US Food and Drug Administration for use in combination with fluorouracil (FU)-based chemotherapy for first-line treatment of patients with metastatic colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Its mechanism of action is inhibition of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> by neutralizing vascular endothelial growth factor </plain></SENT>
<SENT sid="2" pm="."><plain>Adverse events resulting from its use include gastrointestinal <z:mpath ids='MPATH_81'>perforation</z:mpath>, wound-healing complications, <z:mp ids='MP_0001914'>hemorrhage</z:mp>, and arterial <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We present a case of a 67-year-old man who developed Fournier's <z:hpo ids='HP_0100758'>gangrene</z:hpo> during treatment with bevacizumab 4 months after completing mFOLFOX6 (5-FU/leucovorin/<z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Other than bevacizumab, the patient had no medications and had no medical conditions that would predispose to Fournier's <z:hpo ids='HP_0100758'>gangrene</z:hpo> </plain></SENT>
</text></document>